<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861273</url>
  </required_header>
  <id_info>
    <org_study_id>C0371002</org_study_id>
    <secondary_id>2018-003086-33</secondary_id>
    <nct_id>NCT03861273</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B</brief_title>
  <acronym>BENEGENE-2</acronym>
  <official_title>PHASE 3, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF FIX GENE TRANSFER WITH PF-06838435 (RAAV-SPARK100-HFIX-PADUA) IN ADULT MALE PARTICIPANTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C &lt;=2%) (BENEGENE-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in
      adult male participants with moderately severe to severe hemophilia B (participants that have
      a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce
      genetic material into cells to compensate for missing or non-functioning Factor IX. Eligible
      study participants will have completed a minimum 6 months of routine Factor IX prophylaxis
      therapy during the lead in study (C0371004). Participants will be dosed once (intravenously)
      and will be evaluated over the course of 6 years. The main objectives of the study are to
      compare the annualized bleeding rate [ABR] of the gene therapy to routine prophylaxis from
      the lead-in study and to evaluate the impact that it may have on participant's Factor IX
      circulating activity [FIX:C].
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">April 21, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized bleeding rate (ABR)</measure>
    <time_frame>First 12 months post PF 06838435 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vector derived FIX:C level</measure>
    <time_frame>Week 12 to 12 months post PF 06838435 infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized infusion rate (AIR) of exogenous Factor IX Activity</measure>
    <time_frame>First 12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Factor IX Activity consumption</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized number of bleeding events of specific type: spontaneous and traumatic, and untreated</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of target joint bleeds</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of the participants without bleeds</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in joint health as measured by the Hemophilia Joint Health Score (HJHS) instrument</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Hemophilia Quality of Life (Haem A QoL)</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Hemophilia Activities List (HAL)</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Patient Global Impression of Change-Hemophilia (PGIC-H)</measure>
    <time_frame>12 months post study drug infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector derived Factor IX activity (FIX:C) level at steady state</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized infusion rate (AIR) of exogenous Factor IX</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Factor IX consumption</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized number of bleeding events of specific type: spontaneous and traumatic, and untreated</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of target joint bleeds</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Hemophilia Quality of Life (Haem A QoL)</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Hemophilia Activities List (HAL)</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) instrument - Patient Global Impression of Change - Hemophilia (PGIC-H)</measure>
    <time_frame>Annually for 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of all adverse events collected during the study</measure>
    <time_frame>For the duration of 6 years after PF-06838435 infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>PF-06838435/ fidanacogene elaparvovec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06838435/ fidanacogene elaparvovec</intervention_name>
    <description>Gene Therapy</description>
    <arm_group_label>PF-06838435/ fidanacogene elaparvovec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Males who completed 6 months of routine Factor IX prophylaxis therapy during the lead
             in study (C0371004) and have &gt; = 50 documented exposure days to a FIX protein product
             such as recombinant, plasma-derived or extended half-life FIX product

          -  Moderately severe to severe hemophilia B (Factor IX activity &lt; =2%)

          -  Suspension of prophylaxis therapy for hemophilia B after administration of the study
             drug

          -  Laboratory values (hemoglobin, platelets and creatinine) within study specified limits

          -  Agree to contraception until components of the drug are eliminated from their body

          -  Capable of giving signed informed consent

        Exclusion Criteria

          -  Anti-AAV Spark100 neutralizing antibodies (nAb) titer, above the established threshold
             of 1:1

          -  History of inhibitor to Factor IX or inhibitor detected during screening.

          -  Clinical signs or symptoms of decreased response to Factor IX

          -  Hypersensitivity to Factor IX replacement product or intravenous immunoglobulin
             administration

          -  History of chronic infection or other chronic disease

          -  Any concurrent clinically significant major disease or condition

          -  Laboratory values at screening visit that are abnormal or outside acceptable study
             limits

          -  Significant and/or unstable liver disease, biliary disease, significant liver fibrosis

          -  Planned surgical procedure requiring Factor IX surgical prophylactic factor treatment
             12 months from screening visit

          -  Use of restricted therapies (e.g., blood products, acetylsalicylic acid [aspirin] or
             ibuprofen, other investigational therapy, and by-passing agents)

          -  Participation in a gene therapy research trial at any time or in an interventional
             clinical study within 12 weeks of screening visit

          -  Active hepatitis B or C; hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV)
             deoxyribonucleic acid (DNA) positivity, or hepatitis C virus (HCV) ribonucleic acid
             (RNA) positivity

          -  Serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with Cluster of
             Differentiation 4 positive (CD4+) cell count ≤200 mm3 and/or viral load &gt;20 copies/mL

          -  Study and sponsor staff and their families involved in the conduct of the study

          -  Unable to comply with study procedures

          -  Sensitivity to heparin or heparin induced thrombocytopenia

          -  Sensitivity to any of the study interventions, or components thereof, or drug or other
             allergy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco - Investigational Drug Service (IDS) Pharmacy</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0622</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco - Outpatient Hematology Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital &amp; Health Care Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mississippi Baptist Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Madison Radiological Group</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mississippi Center for Advanced Medicine</name>
      <address>
        <city>Madison</city>
        <state>Mississippi</state>
        <zip>39110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Human Phenomic Science CHPS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Blood Disorder Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Comprehensive Hemophilia &amp; Thrombosis Program, Hospital of University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIO</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20.211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>SÃO Paulo</state>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Centre - Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juravinski Hospital - Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cardiologique Louis Pradel - CRTH</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens &quot;LAIKO&quot;, 2nd Regional Blood Transfusion Center</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital and Research Centre</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital, Department of Hematology, Oncology and Radiation Physics</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ApoEx AB</name>
      <address>
        <city>Malmö</city>
        <zip>211 24</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Sahinbey Training and Research Hospital</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS FT</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle upon Tyne Hospitals NHS FT</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Greece</country>
    <country>Japan</country>
    <country>Saudi Arabia</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C0371002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF 06838435</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>Factor IX</keyword>
  <keyword>FIX</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Infusion</keyword>
  <keyword>rAAV Spark100 hFIX Padua</keyword>
  <keyword>BeneGene 2</keyword>
  <keyword>Hematological Diseases</keyword>
  <keyword>Annualized bleeding rate (ABR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

